Autopsy report · NCT03809624
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
Cause of deathFutility, also funding or business
“Program terminated due to lack of meaningful efficacy signal.”
Life of this trial
- Ran for about 5 years 8 months before it stopped.
- 160 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Inhibrx Biosciences, Inc
- Sponsor type
- Industry
- Conditions
- Metastatic Solid Tumors; Non-small Cell Lung Cancer; Melanoma; Head and Neck Squamous Cell Carcinoma; Gastric Adenocarcinoma; Renal Cell Carcinoma
- Interventions
- INBRX-105 - PDL1x41BB antibody; Pembrolizumab
- Participants
- 160
- Sites
- 23
- Countries
- United States
Trials that died the same way
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
“The study was terminated due to lack of efficacy.” - Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
“The program was shut down due to a lack of efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - A Study of LY3405105 in Participants With Advanced Cancer
“The study was terminated for lack of sufficient efficacy.” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.